- Current report filing (8-K)
December 11 2008 - 4:11PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13
or 15(d) of
the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported):
December 11, 2008
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
|
0-19700
(Commission File Number)
|
|
33-0266089
(I.R.S. Employer Identification No.)
|
9360 Towne Centre Drive
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrants telephone number, including area
code:
(858)
552-2200
Check the appropriate box below if the Form 8-K is
intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General
Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CRF 240.13e-4(c))
Item 8.01. Other Events.
On December 11, 2008, Amylin
Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food
and Drug Administration has indicated that the ongoing extension of Amylins DURATION-1
study is appropriate to use as the basis for demonstrating comparability between
exenatide once weekly intermediate-scale clinical trial material made at
Alkermes, Incs manufacturing facility and commercial-scale drug product made
at Amylins manufacturing facility. A
copy of the press release is attached as Exhibit 99.1 and is incorporated
herein by reference.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits.
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release
issued by Amylin in December 11, 2008
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AMYLIN
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
Dated: December 11,
2008
|
By:
|
/s/
Lloyd A. Rowland
|
|
|
Lloyd A. Rowland
|
|
|
Vice
President, Governance and Compliance, and
Secretary
|
3
EXHIBIT
INDEX
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release
issued by Amylin on December 11, 2008
|
4
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024